United Therapeutics Corp. (NASDAQ:UTHR) CFO John Maxim Ferrari sold 4,500 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $78.67, for a total value of $354,015.00. Following the completion of the transaction, the chief financial officer now directly owns 407 shares in the company, valued at approximately $32,019. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock.
One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $64.20.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.14% on Tuesday, hitting $77.51. 47,785 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $44.51 and a 1-year high of $79.95. The stock’s 50-day moving average is $74.34 and its 200-day moving average is $67.62. The company has a market cap of $3.870 billion and a P/E ratio of 13.35.
United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 24.4% on a year-over-year basis. On average, analysts predict that United Therapeutics Corp. will post $5.99 earnings per share for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.